PMID- 20089009
OWN - NLM
STAT- MEDLINE
DCOM- 20110324
LR  - 20181201
IS  - 1742-1241 (Electronic)
IS  - 1368-5031 (Linking)
VI  - 64
IP  - 2
DP  - 2010 Jan
TI  - Safety and tolerability of rivastigmine transdermal patch compared with 
      rivastigmine capsules in patients switched from donepezil: data from three 
      clinical trials.
PG  - 188-93
LID - 10.1111/j.1742-1241.2009.02253.x [doi]
AB  - OBJECTIVES: To compare the safety and tolerability of switching patients with 
      mild-to-moderate Alzheimer's disease from donepezil to either rivastigmine 
      capsule or transdermal patch. METHODS: Three studies investigated the switch from 
      donepezil to rivastigmine; study US13 was a 26-week, single-arm, immediate-switch 
      study; US18 was a 26-week, sequential cohort study (both studies evaluated 
      rivastigmine capsules 3-12 mg/day); study US38 was a 25-week, randomised, 
      parallel-group, open-label study which investigated switch (immediate or after 7 
      days' withdrawal) from donepezil to rivastigmine transdermal patch (4.6 mg/24 
      hr). Safety outcomes included adverse events (AEs), discontinuations caused by 
      AEs and serious AEs (SAEs). RESULTS: Patient groups receiving rivastigmine patch 
      (n = 261) or capsules (n = 331) had mean +/- SD ages of 77.3 +/- 8.0 and 78.1 +/- 
      7.8 years, dementia durations of 3.9 +/- 2.6 and 3.6 +/- 2.2 years and 
      Mini-Mental State Examination scores of 18.3 +/- 4.00 and 17.9 +/- 4.4 
      respectively. Overall, 184 (70.5%) and 276 (83.4%) patients experienced at least 
      one AE, and 23 (8.8%) and 55 (16.6%) patients experienced an SAE with the 
      rivastigmine patch and capsules respectively. Of the patients who experienced an 
      AE, 10 (3.8%) and 109 (32.9%) experienced nausea, and 11 (4.2%) and 80 (24.1%) 
      experienced vomiting with the rivastigmine patch and capsules respectively. 
      Discontinuations because of AEs occurred in 64 (19.3%) patients receiving 
      capsules and 38 (14.6%) patients in the transdermal patch group. The most common 
      reasons for discontinuation with the transdermal patch were application site 
      reaction and disease progression, and nausea and vomiting with the capsules. 
      CONCLUSIONS: The rivastigmine transdermal patch appears to have better 
      tolerability than rivastigmine capsules, with fewer gastrointestinal AEs and 
      discontinuations because of these AEs. Simple daily rotation of patch location 
      will likely reduce the frequency of skin reactions. This post hoc analysis was 
      carried out by Novartis Pharmaceuticals Corporation. Data for the analysis were 
      collected from the US13 study (CENA713B US13), the US18 study (CENA713B US18) and 
      the US38 study (CENA713D US38).
FAU - Sadowsky, C H
AU  - Sadowsky CH
AD  - Nova SE University, Fort Lauderdale, FL, USA. CHsadow@aol.com
FAU - Farlow, M R
AU  - Farlow MR
FAU - Meng, X
AU  - Meng X
FAU - Olin, J T
AU  - Olin JT
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PL  - India
TA  - Int J Clin Pract
JT  - International journal of clinical practice
JID - 9712381
RN  - 0 (Capsules)
RN  - 0 (Cholinesterase Inhibitors)
RN  - 0 (Indans)
RN  - 0 (Phenylcarbamates)
RN  - 0 (Piperidines)
RN  - 8SSC91326P (Donepezil)
RN  - PKI06M3IW0 (Rivastigmine)
SB  - IM
MH  - Administration, Cutaneous
MH  - Administration, Oral
MH  - Aged
MH  - Alzheimer Disease/*drug therapy
MH  - Blood Pressure/drug effects
MH  - Capsules
MH  - Cholinesterase Inhibitors/*administration & dosage/adverse effects
MH  - Donepezil
MH  - Female
MH  - Humans
MH  - Indans/*administration & dosage/adverse effects
MH  - Male
MH  - Phenylcarbamates/*administration & dosage/adverse effects
MH  - Piperidines/*administration & dosage/adverse effects
MH  - Pulse
MH  - Randomized Controlled Trials as Topic
MH  - Respiration/drug effects
MH  - Rivastigmine
EDAT- 2010/01/22 06:00
MHDA- 2011/03/25 06:00
CRDT- 2010/01/22 06:00
PHST- 2010/01/22 06:00 [entrez]
PHST- 2010/01/22 06:00 [pubmed]
PHST- 2011/03/25 06:00 [medline]
AID - IJCP2253 [pii]
AID - 10.1111/j.1742-1241.2009.02253.x [doi]
PST - ppublish
SO  - Int J Clin Pract. 2010 Jan;64(2):188-93. doi: 10.1111/j.1742-1241.2009.02253.x.